Pyrrolidone carboxylic acid → Amsacrine

HRID 1248799

반응식

HRID 1248799 반응식
[CH3:1][O:2][C:3]1[CH:4]=[C:5]([NH:24][S:25]([CH3:28])(=[O:27])=[O:26])[CH:6]=[CH:7][C:8]=1[NH:9][C:10]1[C:11]2[CH:12]=[CH:13][CH:14]=[CH:15][C:16]=2[N:17]=[C:18]2[CH:23]=[CH:22][CH:21]=[CH:20][C:19]=12.C([O-])(=O)[C@H](C)O.N1C(=O)CCC1C(O)=O>>[CH3:1][O:2][C:3]1[CH:4]=[C:5]([NH:24][S:25]([CH3:28])(=[O:27])=[O:26])[CH:6]=[CH:7][C:8]=1[NH:9][C:10]1[C:19]2[CH:20]=[CH:21][CH:22]=[CH:23][C:18]=2[N:17]=[C:16]2[CH:15]=[CH:14][CH:13]=[CH:12][C:11]=12

참가 물질

3

반응물 2

HCID 499Pyrrolidone carboxylic acidHCID 131714982m-AMSA L(+)-lactate

생성물 1

HCID 2179Amsacrine

실험 절차

In the above formulations, a mixture of m-AMSA-L(+)-lactate and 1 mole equivalent of D,L-pyroglutamic acid will provide a 5 mg/ml m-AMSA solution which will not precipitate. The use of L-pyroglutamic acid in place of D,L-pyroglutamic acid will provide a 5 to 7.5 mg/ml solution which will not precipitate.

출처 및 근거

ORD 기록
ord-0a1da1abd6fe41149c85380bf6a9739e
출처 데이터셋
uspto-grants-1986_12
특허 번호
US04626541

연결된 노트

불러오는 중…